Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672310 | 0.91 | THRB (0.44) | THRBTHRASLC29A1ADRA2AADRA1A | |
| SCHEMBL13327007 | 0.88 | THRB (0.45) | THRBTHRASLC29A1MAPT | |
| SCHEMBL16597545 | 0.87 | THRB (0.49) | THRBTHRASLC29A1ADRA2AADRA1A | |
| SCHEMBL673561 | 0.86 | THRB (0.48) | THRBTHRASLC29A1MAPTDGKA | |
| SCHEMBL10079025 | 0.86 | THRB (0.51) | THRBTHRASLC29A1MAPTDGKA | |
| SCHEMBL13327010 | 0.84 | THRB (0.41) | THRBTHRASLC29A1ADRA2AADRA1A | |
| SCHEMBL28146 | 0.83 | THRB (0.56) | THRBTHRAMAPTDGKA | |
| SCHEMBL674504 | 0.81 | HRH3 (0.44) | THRBTHRAHRH3 | |
| SCHEMBL2354033 | 0.81 | TSHR (0.32) | THRBTHRAMGLLSLC29A1DRD3 | |
| SCHEMBL9327544 | 0.81 | TSHR (0.43) | THRBTHRASLC29A1DGKAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283550-B1 | CATALYST CONTAINING AMIDINE GROUPS | SIKA TECH AG (CH) | 2020-12-16 | — | — | EP | disclosed |
| CN-107428941-B | Amidino group-containing catalyst | SIKA技术股份公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10392480-B2 | Catalyst containing amidine groups | SIKA TECHNOLOGY AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180171082-A1 | CATALYST CONTAINING AMIDINE GROUPS | SIKA TECHNOLOGY AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-7714076-B2 | Acrylic pressure-sensitive adhesives with aziridine crosslinking agents | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714076-B2 | Acrylic pressure-sensitive adhesives with aziridine crosslinking agents | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090246390-A1 | ACRYLIC PRESSURE-SENSITIVE ADHESIVES WITH AZIRIDINE CROSSLINKING AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2009-10-01 | — | — | US | disclosed |
| US-20090246390-A1 | ACRYLIC PRESSURE-SENSITIVE ADHESIVES WITH AZIRIDINE CROSSLINKING AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2009-10-01 | — | — | US | disclosed |
| WO-2009120420-A1 | ACRYLIC PRESSURE-SENSITIVE ADHESIVES WITH AZIRIDINE CROSSLINKING AGENTS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246390-A1 | ACRYLIC PRESSURE-SENSITIVE ADHESIVES WITH AZIRIDINE CROSSLINKING AGENTS | AAAS, CDH1, PTK2 | THRB 4443/4885THRA 3397/4885MGLL 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.